26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. - XML Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
: 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. - XML Representation

Active as of 2024-05-16
Raw xml | Download


<Citation xmlns="http://hl7.org/fhir">
  <id value="179622"/>
  <meta>
    <versionId value="1"/>
    <lastUpdated value="2023-11-26T22:35:16.629Z"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Citation</b><a name="179622"> </a><a name="hc179622"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceCitation &quot;179622&quot; Version &quot;1&quot; Updated &quot;2023-11-26 22:35:16+0000&quot; </p></div><p><b>url</b>: <code>https://fevir.net/resources/Citation/179622</code></p><p><b>identifier</b>: FEvIR Object Identifier/179622, <code>https://pubmed.ncbi.nlm.nih.gov</code>/26002607</p><p><b>version</b>: 1.0.0-ballot</p><p><b>title</b>: 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.</p><p><b>status</b>: active</p><p><b>date</b>: 2024-05-16 12:17:54+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td>FEvIR Platform Use (Details: Citation Classification Type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')</td><td>Medline Base <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#medline-base)</span></td></tr></table><p><b>jurisdiction</b>: World <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (m49.htm#001)</span></p><p><b>copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>approvalDate</b>: 2016-04-21</p><p><b>lastReviewDate</b>: 2020-02-06</p><p><b>author</b>: Computable Publishing®: MEDLINE-to-FEvIR Converter: </p><blockquote><p><b>classification</b></p><p><b>type</b>: Citation Source <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-classification-type.html">Citation Classification Type</a>#citation-source)</span></p><p><b>classifier</b>: MEDLINE <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: MEDLINE Citation Owner <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-classification-type.html">Citation Classification Type</a>#medline-owner)</span></p><p><b>classifier</b>: National Library of Medicine, Index Section <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (elements_descriptions.html#owner_value#NLM)</span></p></blockquote><p><b>currentState</b>: Medline Citation Status of Medline <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#medline-medline)</span>, PubMed PublicationStatus of ppublish <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-publication-status-ppublish)</span></p><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Received <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-received)</span></p><p><b>period</b>: ?? --&gt; 2015-03-21</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Accepted <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-accepted)</span></p><p><b>period</b>: ?? --&gt; 2015-05-13</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Entrez <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-entrez)</span></p><p><b>period</b>: ?? --&gt; 2015-05-24 06:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Pubmed <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-pubmed)</span></p><p><b>period</b>: ?? --&gt; 2015-05-24 06:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Medline <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-medline)</span></p><p><b>period</b>: ?? --&gt; 2016-04-22 06:00:00+0000</p></blockquote><blockquote><p><b>citedArtifact</b></p><p><b>identifier</b>: <code>https://pubmed.ncbi.nlm.nih.gov</code>/26002607, <code>https://www.ncbi.nlm.nih.gov/pmc/</code>/PMC4511224, <code>https://doi.org</code>/10.1093/annonc/mdv245, pii/S0923-7534(19)31866-6</p><h3>Titles</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Language</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td>Primary title <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-title-type.html">Title Type</a>#primary)</span></td><td>English <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.5.0/CodeSystem-v3-ietf3066.html">Tags for the Identification of Languages</a>#en)</span></td><td>Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.</td></tr></table><h3>Abstracts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Text</b></td><td><b>Copyright</b></td></tr><tr><td style="display: none">*</td><td>Following the results of the TAX-327 study, questions have been raised as to whether administering chemotherapy to men with prostate cancer before symptomatic disease progression when receiving standard hormonal treatment can improve the duration and quality of patient survival. The GETUG-AFU-15 and CHAARTED studies both assessed the efficacy and tolerability of androgen deprivation therapy (ADT) with or without docetaxel in men with metastatic hormone-naive prostate cancer. Both studies included a mix of patients with de novo metastatic disease (∼75%) and patients who developed metastases following treatment of localized disease. A short course of ADT was allowed in both trials prior to accrual. Key differences between the two studies include the number of patients with high-volume metastases (GETUG-AFU-15: 52%; CHAARTED: 65%) and number of docetaxel cycles (GETUG-AFU-15: up to nine cycles; CHAARTED six cycles). Both studies reported an improvement in progression-free survival with docetaxel plus ADT versus ADT alone. The GETUG-AFU-15 did not find a significant difference in the primary end point of overall survival (OS) {hazard ratio (HR) 0.9 [95% confidence interval (CI) 0.7-1.2]; P = 0.44} for ADT plus docetaxel versus ADT alone. The CHAARTED study met the primary end point of OS [HR 0.61 (95% CI 0.47-0.80); P = 0.0003], and in a subset analysis reported the greatest improvement in OS for patients with high-volume disease [HR 0.60 (95% CI 0.45-0.81); P = 0.0006]. The following article debates the results from the GETUG-AFU-15 and CHAARTED studies and asks whether medical practice should be changed for patients with metastatic hormone-naive prostate cancer based on the results of one positive study.</td><td>© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</td></tr></table><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Wu JN, Fish KM, Evans CP et al. . No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2013; 120(6): 818–823.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/24258693/">https://pubmed.ncbi.nlm.nih.gov/24258693/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/24258693</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Center MM, Jemal A, Lortet-Tieulent J et al. . International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61(6): 1079–1092.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/22424666/">https://pubmed.ncbi.nlm.nih.gov/22424666/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/22424666</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Cullen J, Elsamanoudi S, Brassell SA et al. . The burden of prostate cancer in Asian nations. J Carcinog 2012; 11: 7.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/22529743/">https://pubmed.ncbi.nlm.nih.gov/22529743/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/22529743</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Patrikidou A, Loriot Y, Eymard J-C et al. . Who dies from prostate cancer? Prostate Cancer Prostatic Dis 2014; 17(4): 348–352.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/25311767/">https://pubmed.ncbi.nlm.nih.gov/25311767/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/25311767</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Sweeney C, Carducci MA, Eisenberger MA et al. . Chemohormonal therapy versus hormonal therapy for hormone naive newly metastatic prostate cancer: ECOG-led randomized trial. Ann Oncol 2014; (Suppl 4): Abstr 7560.</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Gravis G, Fizazi K, Joly F et al. . Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14(2): 149–158.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/23306100/">https://pubmed.ncbi.nlm.nih.gov/23306100/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/23306100</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Ahmed M, Li L-C. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 2013; 20(4): 362–371.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/23163774/">https://pubmed.ncbi.nlm.nih.gov/23163774/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/23163774</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Tannock IF, de Wit R, Berry WR et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502–1512.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/15470213/">https://pubmed.ncbi.nlm.nih.gov/15470213/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/15470213</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Berthold DR, Pond GR, Soban F et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26(2): 242–245.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/18182665/">https://pubmed.ncbi.nlm.nih.gov/18182665/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/18182665</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Petrylak DP, Tangen CM, Hussain MHA et al. . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513–1520.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/15470214/">https://pubmed.ncbi.nlm.nih.gov/15470214/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/15470214</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Gravis G, Boher J-M, Joly F et al. . Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (Pca): long-term analysis of the GETUG-AFU-15 phase III trial. J Clin Oncol 2015; (GU suppl): abstr 140.</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Sweeney C, Chen Y-H, Carducci MA et al. . Impact on overall survival with chemohormonal therapy versus hormone therapy for hormone-sensitive newly metastatic prostate cancer: an ECOG-led phase III randomized trial. J Clin Oncol 2014; 32(5s): abstr LBA2.</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol 2014; 65(6): 1198–1204.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/23910941/">https://pubmed.ncbi.nlm.nih.gov/23910941/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/23910941</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Harris WP, Mostaghel EA, Nelson PS, Montgomery RB. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6(2): 76–85.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/19198621/">https://pubmed.ncbi.nlm.nih.gov/19198621/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/19198621</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: van Soest RJ, van Royen ME, de Morrée ES et al. . Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49(18): 3821–3830.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/24200698/">https://pubmed.ncbi.nlm.nih.gov/24200698/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/24200698</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Mezynski J, Pezaro C, Bianchini D et al. . Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23(11): 2943–2947.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/22771826/">https://pubmed.ncbi.nlm.nih.gov/22771826/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/22771826</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Nakouzi Al N, Le Moulec S, Albiges L et al. . Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2014; 66: e71–e72.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/25012524/">https://pubmed.ncbi.nlm.nih.gov/25012524/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/25012524</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Payne H, Bahl A, Mason M et al. . Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int 2012; 110(5): 658–667.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/22429837/">https://pubmed.ncbi.nlm.nih.gov/22429837/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/22429837</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Droz J-P, Aapro M, Balducci L et al. . Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15(9): e404–e414.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/25079103/">https://pubmed.ncbi.nlm.nih.gov/25079103/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/25079103</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Stone P, Hardy J, Huddart R et al. . Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36(9): 1134–1141.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10854947/">https://pubmed.ncbi.nlm.nih.gov/10854947/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/10854947</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Nguyen PL, Alibhai SMH, Basaria S et al. . Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67(5): 825–836.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/25097095/">https://pubmed.ncbi.nlm.nih.gov/25097095/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/25097095</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Loriot Y, Fizazi K. Taxanes: still a major weapon in the armamentarium against prostate cancer. Eur Urol 2013; 63(6): 983–985.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/23395593/">https://pubmed.ncbi.nlm.nih.gov/23395593/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/23395593</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Gerritse FL, Meulenbeld HJ, Roodhart JML et al. . Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Eur J Cancer 2013; 49(15): 3176–3183.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/23849828/">https://pubmed.ncbi.nlm.nih.gov/23849828/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/23849828</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Fizazi K, Abrahamsson P-A, Ahlgren G et al. . Achievements and perspectives in prostate cancer phase 3 trials from Genitourinary Research Groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol 2015; 67(5): 904–912.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/25218582/">https://pubmed.ncbi.nlm.nih.gov/25218582/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/25218582</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Eisenberger MA, Blumenstein BA, Crawford ED et al. . Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15): 1036–1042.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9761805/">https://pubmed.ncbi.nlm.nih.gov/9761805/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/9761805</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Crawford ED, Eisenberger MA, McLeod DG et al. . A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7): 419–424.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/2503724/">https://pubmed.ncbi.nlm.nih.gov/2503724/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/2503724</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Hussain M, Tangen CM, Berry DL et al. . Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368(14): 1314–1325.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/23550669/">https://pubmed.ncbi.nlm.nih.gov/23550669/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/23550669</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Millikan RE, Wen S, Pagliaro LC et al. . Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008; 26(36): 5936–5942.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/19029421/">https://pubmed.ncbi.nlm.nih.gov/19029421/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/19029421</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Tait C, Moore D, Hodgson C et al. . Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int 2014; 114(6b): E70–E73.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/24589330/">https://pubmed.ncbi.nlm.nih.gov/24589330/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/24589330</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Gravis G, Boher J-M, Fizazi K et al. . Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the Glass Model and development of a novel simplified prognostic model. Eur Urol 2014. Sep 29 [epub ahead of print], doi: 10.1016/j.eururo.2014.09.022.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/25277272/">https://pubmed.ncbi.nlm.nih.gov/25277272/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/25277272</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: James ND, Spears MR, Clarke NW et al. . Survival with newly diagnosed metastatic prostate cancer in the ‘docetaxel era’: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67(6): 1028–1038.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/25301760/">https://pubmed.ncbi.nlm.nih.gov/25301760/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/25301760</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57(2): 229–233.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9000560/">https://pubmed.ncbi.nlm.nih.gov/9000560/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/9000560</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253–265.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/15057285/">https://pubmed.ncbi.nlm.nih.gov/15057285/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/15057285</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Mercader M, Sengupta S, Bodner BK et al. . Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int 2007; 99(1): 60–67.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/17227493/">https://pubmed.ncbi.nlm.nih.gov/17227493/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/17227493</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Ioannidis J. Why most published research findings are false. PLoS Med 2005; 2(8): e124.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/16060722/">https://pubmed.ncbi.nlm.nih.gov/16060722/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/16060722</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Templeton AJ, Vera-Badillo FE, Wang L et al. . Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24(12): 2972–2977.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/24126362/">https://pubmed.ncbi.nlm.nih.gov/24126362/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/24126362</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Gravis G, Marino P, Joly F et al. . Patients self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 2014; 50(5): 953–962.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/24424105/">https://pubmed.ncbi.nlm.nih.gov/24424105/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/24424105</span></p></blockquote><blockquote><p><b>publicationForm</b></p><h3>PublishedIns</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Identifier</b></td><td><b>Title</b></td><td><b>PublisherLocation</b></td></tr><tr><td style="display: none">*</td><td>Periodical <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-published-in-type.html">Published In Type</a>#D020492)</span></td><td>Electronic ISSN Type/1569-8041, ISOAbbreviation/Ann Oncol, ISSN Linking/0923-7534, Medline Title Abbreviation/Ann Oncol, NLM Unique ID/9007735</td><td>Annals of oncology : official journal of the European Society for Medical Oncology</td><td>England</td></tr></table><p><b>citedMedium</b>: Internet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-medium.html">Cited Medium</a>#internet)</span></p><p><b>volume</b>: 26</p><p><b>issue</b>: 8</p><p><b>articleDate</b>: 2015-08</p><p><b>publicationDateText</b>: 2015-Aug</p><p><b>language</b>: English <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.5.0/CodeSystem-v3-ietf3066.html">Tags for the Identification of Languages</a>#en)</span></p><p><b>pageString</b>: 1660-7</p></blockquote><blockquote><p><b>publicationForm</b></p><p><b>citedMedium</b>: Internet without issue <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-medium.html">Cited Medium</a>#internet-without-issue)</span></p><p><b>articleDate</b>: 2015-05-22</p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: Abstract <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-artifact-url-classifier.html">Artifact Url Classifier</a>#abstract)</span></p><p><b>url</b>: <a href="https://pubmed.ncbi.nlm.nih.gov/26002607/">https://pubmed.ncbi.nlm.nih.gov/26002607/</a></p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: DOI Based <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-artifact-url-classifier.html">Artifact Url Classifier</a>#doi-based)</span></p><p><b>url</b>: <a href="https://doi.org/10.1093/annonc/mdv245">https://doi.org/10.1093/annonc/mdv245</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Publishing Model <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#publishing-model)</span></p><p><b>classifier</b>: Print Electronic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#Print-Electronic)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Keyword <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#keyword)</span></p><p><b>artifactAssessment</b>: <a name="hckeywords0"> </a></p><blockquote><p/><p><a name="keywords0"> </a></p><p><a name="hckeywords0"> </a></p><p><b>artifact</b>: <a href="#">#</a></p><blockquote><p><b>content</b></p><p><b>classifier</b>: ADT <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>content</b></p><p><b>classifier</b>: de novo metastatic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>content</b></p><p><b>classifier</b>: docetaxel <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>content</b></p><p><b>classifier</b>: hormone-naive <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>content</b></p><p><b>classifier</b>: prostate <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote></blockquote></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Chemical <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#chemical)</span></p><p><b>classifier</b>: Androgen Antagonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000726)</span>, Taxoids <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D043823)</span>, Docetaxel <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (chemical-substances#15H5577CQD; #D000077143)</span>, Gonadotropin-Releasing Hormone <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (chemical-substances#33515-09-2; #D007987)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: MeSH Heading <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading)</span></p><p><b>artifactAssessment</b>: <a name="hcmeshHeading0"> </a></p><blockquote><p/><p><a name="meshHeading0"> </a></p><p><a name="hcmeshHeading0"> </a></p><p><b>artifact</b>: <a href="#">#</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Androgen Antagonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000726)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration &amp; dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Antineoplastic Combined Chemotherapy Protocols <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000971)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Bone Neoplasms <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D001859)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: drug therapy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000188)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000556)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Disease Progression <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D018450)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Disease-Free Survival <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D018572)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Docetaxel <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000077143)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Gonadotropin-Releasing Hormone <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D007987)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: agonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000819)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Humans <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D006801)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Male <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008297)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Orchiectomy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D009919)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is Major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Proportional Hazards Models <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016016)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Prostatic Neoplasms <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D011471)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: drug therapy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000188)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: pathology <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000473)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Standard of Care <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D059039)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Taxoids <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D043823)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration &amp; dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote></blockquote></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Publication Type <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#publication-type)</span></p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016428)</span>, Research Support, Non-U.S. Gov't <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D013485)</span>, Review <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016454)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Knowledge Artifact Type <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#knowledge-artifact-type)</span></p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>artifactAssessment</b>: <span>: Classifier added by Computable Publishing LLC</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Citation Subset <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#citation-subset)</span></p><p><b>classifier</b>: IM <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (elements_descriptions.html#citationsubset#IM)</span></p></blockquote><blockquote><p><b>contributorship</b></p><p><b>complete</b>: true</p><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor0"> </a></p><blockquote><p/><p><a name="author0"> </a></p><p><a name="hcauthor0"> </a></p><p><b>name</b>: K Fizazi </p></blockquote><p><b>forenameInitials</b>: K</p><p><b>affiliation</b>: <span>: Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Paris, France.</span></p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor1"> </a></p><blockquote><p/><p><a name="author1"> </a></p><p><a name="hcauthor1"> </a></p><p><b>name</b>: C Jenkins </p></blockquote><p><b>forenameInitials</b>: C</p><p><b>affiliation</b>: <span>: Med Ed, RMC, Exeter, UK.</span></p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor2"> </a></p><blockquote><p/><p><a name="author2"> </a></p><p><a name="hcauthor2"> </a></p><p><b>name</b>: I F Tannock </p></blockquote><p><b>forenameInitials</b>: IF</p><p><b>affiliation</b>: <span>: Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada ian.tannock@uhn.ca.</span></p></blockquote></blockquote></blockquote><hr/><blockquote><p><b>Generated Narrative: ArtifactAssessment #keywords0</b><a name="keywords0"> </a><a name="hckeywords0"> </a></p><p><b>artifact</b>: <a href="#">#</a></p><blockquote><p><b>content</b></p><p><b>classifier</b>: ADT <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>content</b></p><p><b>classifier</b>: de novo metastatic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>content</b></p><p><b>classifier</b>: docetaxel <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>content</b></p><p><b>classifier</b>: hormone-naive <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>content</b></p><p><b>classifier</b>: prostate <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author0</b><a name="author0"> </a><a name="hcauthor0"> </a></p><p><b>name</b>: K Fizazi </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author1</b><a name="author1"> </a><a name="hcauthor1"> </a></p><p><b>name</b>: C Jenkins </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author2</b><a name="author2"> </a><a name="hcauthor2"> </a></p><p><b>name</b>: I F Tannock </p></blockquote><hr/><blockquote><p><b>Generated Narrative: ArtifactAssessment #meshHeading0</b><a name="meshHeading0"> </a><a name="hcmeshHeading0"> </a></p><p><b>artifact</b>: <a href="#">#</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Androgen Antagonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000726)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration &amp; dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Antineoplastic Combined Chemotherapy Protocols <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000971)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Bone Neoplasms <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D001859)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: drug therapy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000188)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000556)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Disease Progression <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D018450)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Disease-Free Survival <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D018572)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Docetaxel <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000077143)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Gonadotropin-Releasing Hormone <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D007987)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: agonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000819)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Humans <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D006801)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Male <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008297)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Orchiectomy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D009919)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is Major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Proportional Hazards Models <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016016)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Prostatic Neoplasms <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D011471)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: drug therapy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000188)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: pathology <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000473)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Standard of Care <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D059039)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading &quot;MeSH heading&quot;)</span></p><p><b>classifier</b>: Taxoids <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D043823)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration &amp; dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote></blockquote></div>
  </text>
  <contained>
    <ArtifactAssessment>
      <id value="keywords0"/>
      <artifactReference>
        <reference value="#"/>
        <type value="Citation"/>
      </artifactReference>
      <content>
        <classifier>
          <text value="ADT"/>
        </classifier>
      </content>
      <content>
        <classifier>
          <text value="de novo metastatic"/>
        </classifier>
      </content>
      <content>
        <classifier>
          <text value="docetaxel"/>
        </classifier>
      </content>
      <content>
        <classifier>
          <text value="hormone-naive"/>
        </classifier>
      </content>
      <content>
        <classifier>
          <text value="prostate"/>
        </classifier>
      </content>
    </ArtifactAssessment>
  </contained>
  <contained>
    <Practitioner>
      <id value="author0"/>
      <name>
        <family value="Fizazi"/>
        <given value="K"/>
      </name>
    </Practitioner>
  </contained>
  <contained>
    <Practitioner>
      <id value="author1"/>
      <name>
        <family value="Jenkins"/>
        <given value="C"/>
      </name>
    </Practitioner>
  </contained>
  <contained>
    <Practitioner>
      <id value="author2"/>
      <name>
        <family value="Tannock"/>
        <given value="I F"/>
      </name>
    </Practitioner>
  </contained>
  <contained>
    <ArtifactAssessment>
      <id value="meshHeading0"/>
      <artifactReference>
        <reference value="#"/>
        <type value="Citation"/>
      </artifactReference>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D000726"/>
            <display value="Androgen Antagonists"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000008"/>
              <display value="administration &amp; dosage"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49487"/>
                <display value="No"/>
              </coding>
            </classifier>
          </component>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D000971"/>
            <display value="Antineoplastic Combined Chemotherapy Protocols"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000627"/>
              <display value="therapeutic use"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49488"/>
                <display value="Yes"/>
              </coding>
            </classifier>
          </component>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D001859"/>
            <display value="Bone Neoplasms"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000188"/>
              <display value="drug therapy"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49488"/>
                <display value="Yes"/>
              </coding>
            </classifier>
          </component>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000556"/>
              <display value="secondary"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49487"/>
                <display value="No"/>
              </coding>
            </classifier>
          </component>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D018450"/>
            <display value="Disease Progression"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D018572"/>
            <display value="Disease-Free Survival"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D000077143"/>
            <display value="Docetaxel"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D007987"/>
            <display value="Gonadotropin-Releasing Hormone"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000819"/>
              <display value="agonists"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49488"/>
                <display value="Yes"/>
              </coding>
            </classifier>
          </component>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D006801"/>
            <display value="Humans"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D008297"/>
            <display value="Male"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D009919"/>
            <display value="Orchiectomy"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is Major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D016016"/>
            <display value="Proportional Hazards Models"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D011471"/>
            <display value="Prostatic Neoplasms"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000188"/>
              <display value="drug therapy"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49488"/>
                <display value="Yes"/>
              </coding>
            </classifier>
          </component>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000473"/>
              <display value="pathology"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49487"/>
                <display value="No"/>
              </coding>
            </classifier>
          </component>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D059039"/>
            <display value="Standard of Care"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
      </content>
      <content>
        <informationType value="classifier"/>
        <type>
          <coding>
            <system
                    value="http://hl7.org/fhir/cited-artifact-classification-type"/>
            <code value="mesh-heading"/>
            <display value="MeSH heading"/>
          </coding>
          <text value="components (if present) include qualifier codings"/>
        </type>
        <classifier>
          <coding>
            <system value="https://meshb.nlm.nih.gov/"/>
            <code value="D043823"/>
            <display value="Taxoids"/>
            <userSelected value="false"/>
          </coding>
        </classifier>
        <freeToShare value="true"/>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <text value="is not a major topic"/>
          </classifier>
        </component>
        <component>
          <type>
            <text value="qualifier"/>
          </type>
          <classifier>
            <coding>
              <system value="https://meshb.nlm.nih.gov/"/>
              <code value="Q000008"/>
              <display value="administration &amp; dosage"/>
            </coding>
          </classifier>
          <component>
            <type>
              <text value="is Major topic"/>
            </type>
            <classifier>
              <coding>
                <system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
                <code value="C49487"/>
                <display value="No"/>
              </coding>
            </classifier>
          </component>
        </component>
      </content>
    </ArtifactAssessment>
  </contained>
  <url value="https://fevir.net/resources/Citation/179622"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="179622"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <system value="https://pubmed.ncbi.nlm.nih.gov"/>
    <value value="26002607"/>
  </identifier>
  <version value="1.0.0-ballot"/>
  <title
         value="26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra."/>
  <status value="active"/>
  <date value="2024-05-16T12:17:54+00:00"/>
  <publisher value="HL7 International / Clinical Decision Support"/>
  <contact>
    <name value="HL7 International / Clinical Decision Support"/>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/dss"/>
    </telecom>
  </contact>
  <description
               value="This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
  <useContext>
    <code>
      <system value="http://hl7.org/fhir/citation-classification-type"/>
      <code value="fevir-platform-use"/>
      <display value="FEvIR Platform Use"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
        <code value="medline-base"/>
        <display value="Medline Base"/>
        <userSelected value="false"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <jurisdiction>
    <coding>
      <system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
      <code value="001"/>
      <display value="World"/>
    </coding>
  </jurisdiction>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <approvalDate value="2016-04-21"/>
  <lastReviewDate value="2020-02-06"/>
  <author>
    <name value="Computable Publishing®: MEDLINE-to-FEvIR Converter"/>
  </author>
  <classification>
    <type>
      <coding>
        <system value="http://hl7.org/fhir/citation-classification-type"/>
        <code value="citation-source"/>
        <display value="Citation Source"/>
      </coding>
    </type>
    <classifier>
      <text value="MEDLINE"/>
    </classifier>
  </classification>
  <classification>
    <type>
      <coding>
        <system value="http://hl7.org/fhir/citation-classification-type"/>
        <code value="medline-owner"/>
        <display value="MEDLINE Citation Owner"/>
      </coding>
    </type>
    <classifier>
      <coding>
        <system
                value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value"/>
        <code value="NLM"/>
        <display value="National Library of Medicine, Index Section"/>
        <userSelected value="false"/>
      </coding>
    </classifier>
  </classification>
  <currentState>
    <coding>
      <system value="http://hl7.org/fhir/citation-status-type"/>
      <code value="medline-medline"/>
      <display value="Medline Citation Status of Medline"/>
    </coding>
  </currentState>
  <currentState>
    <coding>
      <system value="http://hl7.org/fhir/citation-status-type"/>
      <code value="pubmed-publication-status-ppublish"/>
      <display value="PubMed PublicationStatus of ppublish"/>
    </coding>
  </currentState>
  <statusDate>
    <activity>
      <coding>
        <system value="http://hl7.org/fhir/citation-status-type"/>
        <code value="pubmed-pubstatus-received"/>
        <display value="PubMed Pubstatus of Received"/>
      </coding>
    </activity>
    <period>
      <end value="2015-03-21"/>
    </period>
  </statusDate>
  <statusDate>
    <activity>
      <coding>
        <system value="http://hl7.org/fhir/citation-status-type"/>
        <code value="pubmed-pubstatus-accepted"/>
        <display value="PubMed Pubstatus of Accepted"/>
      </coding>
    </activity>
    <period>
      <end value="2015-05-13"/>
    </period>
  </statusDate>
  <statusDate>
    <activity>
      <coding>
        <system value="http://hl7.org/fhir/citation-status-type"/>
        <code value="pubmed-pubstatus-entrez"/>
        <display value="PubMed Pubstatus of Entrez"/>
      </coding>
    </activity>
    <period>
      <end value="2015-05-24T06:00:00.000Z"/>
    </period>
  </statusDate>
  <statusDate>
    <activity>
      <coding>
        <system value="http://hl7.org/fhir/citation-status-type"/>
        <code value="pubmed-pubstatus-pubmed"/>
        <display value="PubMed Pubstatus of Pubmed"/>
      </coding>
    </activity>
    <period>
      <end value="2015-05-24T06:00:00.000Z"/>
    </period>
  </statusDate>
  <statusDate>
    <activity>
      <coding>
        <system value="http://hl7.org/fhir/citation-status-type"/>
        <code value="pubmed-pubstatus-medline"/>
        <display value="PubMed Pubstatus of Medline"/>
      </coding>
    </activity>
    <period>
      <end value="2016-04-22T06:00:00.000Z"/>
    </period>
  </statusDate>
  <citedArtifact>
    <identifier>
      <system value="https://pubmed.ncbi.nlm.nih.gov"/>
      <value value="26002607"/>
    </identifier>
    <identifier>
      <system value="https://www.ncbi.nlm.nih.gov/pmc/"/>
      <value value="PMC4511224"/>
    </identifier>
    <identifier>
      <system value="https://doi.org"/>
      <value value="10.1093/annonc/mdv245"/>
    </identifier>
    <identifier>
      <type>
        <coding>
          <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
          <code value="ACSN"/>
          <display value="Accession ID"/>
        </coding>
        <text value="pii"/>
      </type>
      <value value="S0923-7534(19)31866-6"/>
    </identifier>
    <title>
      <type>
        <coding>
          <system value="http://hl7.org/fhir/title-type"/>
          <code value="primary"/>
          <display value="Primary title"/>
        </coding>
      </type>
      <language>
        <coding>
          <system value="urn:ietf:bcp:47"/>
          <code value="en"/>
          <display value="English"/>
        </coding>
      </language>
      <text
            value="Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra."/>
    </title>
    <abstract>
      <text
            value="Following the results of the TAX-327 study, questions have been raised as to whether administering chemotherapy to men with prostate cancer before symptomatic disease progression when receiving standard hormonal treatment can improve the duration and quality of patient survival. The GETUG-AFU-15 and CHAARTED studies both assessed the efficacy and tolerability of androgen deprivation therapy (ADT) with or without docetaxel in men with metastatic hormone-naive prostate cancer. Both studies included a mix of patients with de novo metastatic disease (∼75%) and patients who developed metastases following treatment of localized disease. A short course of ADT was allowed in both trials prior to accrual. Key differences between the two studies include the number of patients with high-volume metastases (GETUG-AFU-15: 52%; CHAARTED: 65%) and number of docetaxel cycles (GETUG-AFU-15: up to nine cycles; CHAARTED six cycles). Both studies reported an improvement in progression-free survival with docetaxel plus ADT versus ADT alone. The GETUG-AFU-15 did not find a significant difference in the primary end point of overall survival (OS) {hazard ratio (HR) 0.9 [95% confidence interval (CI) 0.7-1.2]; P = 0.44} for ADT plus docetaxel versus ADT alone. The CHAARTED study met the primary end point of OS [HR 0.61 (95% CI 0.47-0.80); P = 0.0003], and in a subset analysis reported the greatest improvement in OS for patients with high-volume disease [HR 0.60 (95% CI 0.45-0.81); P = 0.0006]. The following article debates the results from the GETUG-AFU-15 and CHAARTED studies and asks whether medical practice should be changed for patients with metastatic hormone-naive prostate cancer based on the results of one positive study."/>
      <copyright
                 value="© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com."/>
    </abstract>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Wu JN, Fish KM, Evans CP et al. . No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2013; 120(6): 818–823."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/24258693/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="24258693"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Center MM, Jemal A, Lortet-Tieulent J et al. . International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61(6): 1079–1092."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/22424666/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="22424666"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Cullen J, Elsamanoudi S, Brassell SA et al. . The burden of prostate cancer in Asian nations. J Carcinog 2012; 11: 7."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/22529743/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="22529743"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Patrikidou A, Loriot Y, Eymard J-C et al. . Who dies from prostate cancer? Prostate Cancer Prostatic Dis 2014; 17(4): 348–352."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/25311767/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="25311767"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="Sweeney C, Carducci MA, Eisenberger MA et al. . Chemohormonal therapy versus hormonal therapy for hormone naive newly metastatic prostate cancer: ECOG-led randomized trial. Ann Oncol 2014; (Suppl 4): Abstr 7560."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Gravis G, Fizazi K, Joly F et al. . Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14(2): 149–158."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/23306100/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="23306100"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Ahmed M, Li L-C. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 2013; 20(4): 362–371."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/23163774/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="23163774"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Tannock IF, de Wit R, Berry WR et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502–1512."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/15470213/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="15470213"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Berthold DR, Pond GR, Soban F et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26(2): 242–245."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/18182665/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="18182665"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Petrylak DP, Tangen CM, Hussain MHA et al. . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513–1520."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/15470214/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="15470214"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="Gravis G, Boher J-M, Joly F et al. . Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (Pca): long-term analysis of the GETUG-AFU-15 phase III trial. J Clin Oncol 2015; (GU suppl): abstr 140."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <citation
                value="Sweeney C, Chen Y-H, Carducci MA et al. . Impact on overall survival with chemohormonal therapy versus hormone therapy for hormone-sensitive newly metastatic prostate cancer: an ECOG-led phase III randomized trial. J Clin Oncol 2014; 32(5s): abstr LBA2."/>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol 2014; 65(6): 1198–1204."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/23910941/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="23910941"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Harris WP, Mostaghel EA, Nelson PS, Montgomery RB. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6(2): 76–85."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/19198621/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="19198621"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="van Soest RJ, van Royen ME, de Morrée ES et al. . Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49(18): 3821–3830."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/24200698/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="24200698"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Mezynski J, Pezaro C, Bianchini D et al. . Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23(11): 2943–2947."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/22771826/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="22771826"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Nakouzi Al N, Le Moulec S, Albiges L et al. . Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2014; 66: e71–e72."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/25012524/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="25012524"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Payne H, Bahl A, Mason M et al. . Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int 2012; 110(5): 658–667."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/22429837/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="22429837"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Droz J-P, Aapro M, Balducci L et al. . Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15(9): e404–e414."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/25079103/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="25079103"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Stone P, Hardy J, Huddart R et al. . Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36(9): 1134–1141."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/10854947/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="10854947"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Nguyen PL, Alibhai SMH, Basaria S et al. . Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67(5): 825–836."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/25097095/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="25097095"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Loriot Y, Fizazi K. Taxanes: still a major weapon in the armamentarium against prostate cancer. Eur Urol 2013; 63(6): 983–985."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/23395593/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="23395593"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Gerritse FL, Meulenbeld HJ, Roodhart JML et al. . Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Eur J Cancer 2013; 49(15): 3176–3183."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/23849828/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="23849828"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Fizazi K, Abrahamsson P-A, Ahlgren G et al. . Achievements and perspectives in prostate cancer phase 3 trials from Genitourinary Research Groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol 2015; 67(5): 904–912."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/25218582/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="25218582"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Eisenberger MA, Blumenstein BA, Crawford ED et al. . Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15): 1036–1042."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/9761805/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="9761805"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Crawford ED, Eisenberger MA, McLeod DG et al. . A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7): 419–424."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/2503724/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="2503724"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Hussain M, Tangen CM, Berry DL et al. . Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368(14): 1314–1325."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/23550669/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="23550669"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Millikan RE, Wen S, Pagliaro LC et al. . Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008; 26(36): 5936–5942."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/19029421/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="19029421"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Tait C, Moore D, Hodgson C et al. . Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int 2014; 114(6b): E70–E73."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/24589330/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="24589330"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Gravis G, Boher J-M, Fizazi K et al. . Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the Glass Model and development of a novel simplified prognostic model. Eur Urol 2014. Sep 29 [epub ahead of print], doi: 10.1016/j.eururo.2014.09.022."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/25277272/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="25277272"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="James ND, Spears MR, Clarke NW et al. . Survival with newly diagnosed metastatic prostate cancer in the ‘docetaxel era’: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67(6): 1028–1038."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/25301760/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="25301760"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57(2): 229–233."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/9000560/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="9000560"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253–265."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/15057285/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="15057285"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Mercader M, Sengupta S, Bodner BK et al. . Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int 2007; 99(1): 60–67."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/17227493/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="17227493"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Ioannidis J. Why most published research findings are false. PLoS Med 2005; 2(8): e124."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/16060722/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="16060722"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Templeton AJ, Vera-Badillo FE, Wang L et al. . Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24(12): 2972–2977."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/24126362/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="24126362"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <relatesTo>
      <type value="cites"/>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
        </coding>
      </classifier>
      <citation
                value="Gravis G, Marino P, Joly F et al. . Patients self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 2014; 50(5): 953–962."/>
      <document>
        <url value="https://pubmed.ncbi.nlm.nih.gov/24424105/"/>
      </document>
      <resourceReference>
        <identifier>
          <system value="https://pubmed.ncbi.nlm.nih.gov"/>
          <value value="24424105"/>
          <assigner>
            <display value="NLM"/>
          </assigner>
        </identifier>
      </resourceReference>
    </relatesTo>
    <publicationForm>
      <publishedIn>
        <type>
          <coding>
            <system value="http://hl7.org/fhir/published-in-type"/>
            <code value="D020492"/>
            <display value="Periodical"/>
          </coding>
        </type>
        <identifier>
          <type>
            <coding>
              <system
                      value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn"/>
              <code value="Electronic"/>
              <display value="Electronic"/>
            </coding>
            <text value="Electronic ISSN Type"/>
          </type>
          <system value="https://portal.issn.org"/>
          <value value="1569-8041"/>
        </identifier>
        <identifier>
          <type>
            <coding>
              <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
              <code value="XX"/>
              <display value="Organization identifier"/>
            </coding>
            <text value="ISOAbbreviation"/>
          </type>
          <system
                  value="https://www.issn.org/services/online-services/access-to-the-ltwa/"/>
          <value value="Ann Oncol"/>
        </identifier>
        <identifier>
          <type>
            <coding>
              <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
              <code value="XX"/>
              <display value="Organization identifier"/>
            </coding>
            <text value="ISSN Linking"/>
          </type>
          <system
                  value="https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/"/>
          <value value="0923-7534"/>
        </identifier>
        <identifier>
          <type>
            <coding>
              <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
              <code value="XX"/>
              <display value="Organization identifier"/>
            </coding>
            <text value="Medline Title Abbreviation"/>
          </type>
          <system
                  value="https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html"/>
          <value value="Ann Oncol"/>
        </identifier>
        <identifier>
          <type>
            <coding>
              <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
              <code value="XX"/>
              <display value="Organization identifier"/>
            </coding>
            <text value="NLM Unique ID"/>
          </type>
          <system
                  value="https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local"/>
          <value value="9007735"/>
        </identifier>
        <title
               value="Annals of oncology : official journal of the European Society for Medical Oncology"/>
        <publisherLocation value="England"/>
      </publishedIn>
      <citedMedium>
        <coding>
          <system value="http://hl7.org/fhir/cited-medium"/>
          <code value="internet"/>
          <display value="Internet"/>
        </coding>
      </citedMedium>
      <volume value="26"/>
      <issue value="8"/>
      <articleDate value="2015-08"/>
      <publicationDateText value="2015-Aug"/>
      <language>
        <coding>
          <system value="urn:ietf:bcp:47"/>
          <code value="en"/>
          <display value="English"/>
        </coding>
      </language>
      <pageString value="1660-7"/>
    </publicationForm>
    <publicationForm>
      <citedMedium>
        <coding>
          <system value="http://hl7.org/fhir/cited-medium"/>
          <code value="internet-without-issue"/>
          <display value="Internet without issue"/>
        </coding>
      </citedMedium>
      <articleDate value="2015-05-22"/>
    </publicationForm>
    <webLocation>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/artifact-url-classifier"/>
          <code value="abstract"/>
          <display value="Abstract"/>
        </coding>
      </classifier>
      <url value="https://pubmed.ncbi.nlm.nih.gov/26002607/"/>
    </webLocation>
    <webLocation>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/artifact-url-classifier"/>
          <code value="doi-based"/>
          <display value="DOI Based"/>
        </coding>
      </classifier>
      <url value="https://doi.org/10.1093/annonc/mdv245"/>
    </webLocation>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="publishing-model"/>
          <display value="Publishing Model"/>
          <userSelected value="false"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="Print-Electronic"/>
          <display value="Print Electronic"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
    </classification>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="keyword"/>
          <display value="Keyword"/>
          <userSelected value="false"/>
        </coding>
      </type>
      <artifactAssessment>
        <reference value="#keywords0"/>
        <type value="ArtifactAssessment"/>
        <display value="Keywords provided by NOTNLM"/>
      </artifactAssessment>
    </classification>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="chemical"/>
          <display value="Chemical"/>
          <userSelected value="false"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D000726"/>
          <display value="Androgen Antagonists"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D043823"/>
          <display value="Taxoids"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <classifier>
        <coding>
          <system
                  value="https://www.cas.org/support/documentation/chemical-substances"/>
          <code value="15H5577CQD"/>
          <userSelected value="false"/>
        </coding>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D000077143"/>
          <display value="Docetaxel"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <classifier>
        <coding>
          <system
                  value="https://www.cas.org/support/documentation/chemical-substances"/>
          <code value="33515-09-2"/>
          <userSelected value="false"/>
        </coding>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D007987"/>
          <display value="Gonadotropin-Releasing Hormone"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
    </classification>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="mesh-heading"/>
          <display value="MeSH Heading"/>
        </coding>
      </type>
      <artifactAssessment>
        <reference value="#meshHeading0"/>
        <type value="ArtifactAssessment"/>
      </artifactAssessment>
    </classification>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="publication-type"/>
          <display value="Publication Type"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D013485"/>
          <display value="Research Support, Non-U.S. Gov't"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <classifier>
        <coding>
          <system value="https://meshb.nlm.nih.gov/"/>
          <code value="D016454"/>
          <display value="Review"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
    </classification>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="knowledge-artifact-type"/>
          <display value="Knowledge Artifact Type"/>
          <userSelected value="false"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system value="http://hl7.org/fhir/citation-artifact-classifier"/>
          <code value="D016428"/>
          <display value="Journal Article"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
      <artifactAssessment>
        <display value="Classifier added by Computable Publishing LLC"/>
      </artifactAssessment>
    </classification>
    <classification>
      <type>
        <coding>
          <system
                  value="http://hl7.org/fhir/cited-artifact-classification-type"/>
          <code value="citation-subset"/>
          <display value="Citation Subset"/>
          <userSelected value="false"/>
        </coding>
      </type>
      <classifier>
        <coding>
          <system
                  value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset"/>
          <code value="IM"/>
          <display value="IM"/>
          <userSelected value="false"/>
        </coding>
      </classifier>
    </classification>
    <contributorship>
      <complete value="true"/>
      <entry>
        <contributor>
          <reference value="#author0"/>
          <type value="Practitioner"/>
          <display value="Fizazi K"/>
        </contributor>
        <forenameInitials value="K"/>
        <affiliation>
          <display
                   value="Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Paris, France."/>
        </affiliation>
      </entry>
      <entry>
        <contributor>
          <reference value="#author1"/>
          <type value="Practitioner"/>
          <display value="Jenkins C"/>
        </contributor>
        <forenameInitials value="C"/>
        <affiliation>
          <display value="Med Ed, RMC, Exeter, UK."/>
        </affiliation>
      </entry>
      <entry>
        <contributor>
          <reference value="#author2"/>
          <type value="Practitioner"/>
          <display value="Tannock IF"/>
        </contributor>
        <forenameInitials value="IF"/>
        <affiliation>
          <display
                   value="Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada ian.tannock@uhn.ca."/>
        </affiliation>
      </entry>
    </contributorship>
  </citedArtifact>
</Citation>